The Journal of Practical Medicine >

2025 , Vol. 41 >Issue 12: 1825 - 1834

DOI: https://doi.org/10.3969/j.issn.1006-5725.2025.12.008

Basic Research

The effect of pseudouracil modifying enzyme 3 activating AKT pathway on malignant progression of glioblastoma

  • Chang ZHANG ,
  • Chunshan LIU ,
  • Huaying LIAO ,
  • Yuchao WU ,
  • Yunhong TIAN
Expand
  • Department of Radiation Oncology，Affiliated Cancer Hospital & Institute of Guangzhou Medical University，Guangzhou 510095，Guangdong，China

Received date: 2025-01-17

  Online published: 2025-07-02

Fold

Abstract

Objective To investigate the regulatory effects and molecular mechanisms of PUS3 on GBM cell malignant behaviors （proliferation， apoptosis， invasion） in vitro， providing potential therapeutic targets for GBM. Methods The expression of PUS3 in GBM was analyzed using the GEPIA2 database.Kaplan-Meier survival analysis evaluated the survival difference between PUS3 high- and low-expression patients. qRT-PCR and Western blot were performed to detect PUS3 expression in normal glial cells （HEB） and GBM cell lines （U87， LN229， U251， T98G）. PUS3-stably overexpressing GBM cell lines were constructed. Colony formation， CCK-8 assay， and flow cytometry were used to assess proliferation and apoptosis. Transwell assay evaluated cell invasion. Immunohistochemistry （IHC） detected PUS3 expression in GBM patient tissues. Western blot analyzed tumor-related pathway proteins after PUS3 overexpression. Results The expression level of PUS3 is elevated in GBM patient tissues， and the mRNA and protein expression levels in GBM cells are significantly higher than those in HEB cells （P < 0.01）. After overexpression of PUS3， the proliferation ability of GBM cells was enhanced （P < 0.05）， the apoptosis rate decreased （P < 0.01）， and the number of invasive cells increased （P < 0.001）. Mechanistically， overexpression of PUS3 significantly activates the AKT pathway， and the use of AKT inhibitors in PUS3 overexpressing cells can reverse the pro cancer effect. Conclusion PUS3 is highly expressed in glioblastoma （GBM） and promotes tumor cell proliferation， invasion， and apoptosis inhibition by activating the AKT pathway， suggesting its potential as a therapeutic target for GBM treatment.

Key words： pseudouridine synthase 3; glioblastoma; cell proliferation; cell apoptosis; protein kinase B（AKT）

Cite this article

Chang ZHANG , Chunshan LIU , Huaying LIAO , Yuchao WU , Yunhong TIAN . The effect of pseudouracil modifying enzyme 3 activating AKT pathway on malignant progression of glioblastoma[J]. The Journal of Practical Medicine, 2025 , 41(12) : 1825 -1834 . DOI: 10.3969/j.issn.1006-5725.2025.12.008

References

1 CUI Q， YIN K， ZHANG X， et al. Targeting PUS7 suppresses tRNA pseudouridylation and glioblastoma tumorigenesis［J］. Nat Cancer， 2021， 2（9）： 932-949. doi:10.1038/s43018-021-00238-0
2 WELLER M， WEN P Y， CHANG S M， et al. Glioma［J］.Nat Rev Dis Primers， 2024， 10（1）： 33. doi:10.1038/s41572-024-00516-y
3 李梦欣， 惠磊， 汲乾坤， 等. ANXA1在脑胶质母细胞瘤中表达上调并促进胶质母细胞瘤的恶性进展. 实用医学杂志， 2023， 39（8）： 928-935.
4 ZHANG D Y， MING G L， SONG H. PUS7： A targetable epitranscriptomic regulator of glioblastoma growth［J］.Trends Pharmacol Sci， 2021， 42（12）： 976-978. doi:10.1016/j.tips.2021.10.002
5 GLADSON C L， PRAYSON R A， LIU W M. The pathobiology of glioma tumors［J］.. Annu Rev Pathol， 2010， 5： 33-50. doi:10.1146/annurev-pathol-121808-102109
6 LIU K， TSUNG K， ATTENELLO F J. Characterizing Cell Stress and GRP78 in Glioma to Enhance Tumor Treatment［J］.Front Oncol， 2020， 10： 608911. doi:10.3389/fonc.2020.608911
7 YASINJAN F， XING Y， GENG H， et al. Immunotherapy： a promising approach for glioma treatment［J］.Front Immunol， 2023， 14： 1255611. doi:10.3389/fimmu.2023.1255611
8 蔡嘉怡，陈思羽，蔡女略，等.微小RNA-378-5p对胶质瘤血管生成的影响［J］.实用医学杂志，2025，41（2）：186-194.
9 FU M， GU J， WANG M， et al. Emerging roles of tRNA-derived fragments in cancer［J］. Mol Cancer， 2023， 22（1）： 30. doi:10.1186/s12943-023-01739-5
10 PENZO M， MONTANARO L. Turning Uridines around： Role of rRNA Pseudouridylation in Ribosome Biogenesis and Ribosomal Function［J］. Biomolecules， 2018， 8（2）： 38. doi:10.3390/biom8020038
11 ABDELRAHMAN H A， AL‐SHAMSI A M， ALI B R， et al. A null variant in PUS3 confirms its involvement in intellectual disability and further delineates the associated neurodevelopmental disease［J］.Clinical Genetics， 2018， 94（6）： 586-587. doi:10.1111/cge.13443
12 N?stvik M， KATETA S M， Sch?nEWOLF-GREULICH B， et al. Clinical and molecular delineation of PUS3-associated neurodevelopmental disorders［J］. Clin Genet， 2021， 100（5）： 628-633. doi:10.1111/cge.14051
13 SONG D， GUO M， XU S，et al.HSP90-dependent PUS7 overexpression facilitates the metastasis of colorectal cancer cells by regulating LASP1 abundance［J］. J Exp Clin Cancer Res，2021，40（1）：170. doi:10.1186/s13046-021-01951-5
14 HU Y X， DIAO L T， HOU Y R， et al. Pseudouridine synthase 1 promotes hepatocellular carcinoma through mRNA pseudouridylation to enhance the translation of oncogenic mRNAs［J］.Hepatology， 2024， 80（5）： 1058-1073. doi:10.1097/hep.0000000000000702
15 LUO W， XU Z， WANG H， et al. HIF1A-repressed PUS10 regulates NUDC/Cofilin1 dependent renal cell carcinoma migration by promoting the maturation of miR-194-5p［J］.Cell Biosci， 2023， 13（1）： 153. doi:10.1186/s13578-023-01094-4
16 LU S， WEI X， TAO L， et al. A novel tRNA-derived fragment tRF-3022b modulates cell apoptosis and M2 macrophage polarization via binding to cytokines in colorectal cancer［J］. J Hematol Oncol， 2022， 15（1）： 176. doi:10.1186/s13045-022-01388-z
17 CHARETTE M， GRAY M W. Pseudouridine in RNA： What， where， how， and why［J］. IUBMB Life， 2000， 49（5）： 341-351. doi:10.1080/152165400410182
18 GUZZI N， CIE?LA M， NGOC P C T，et al.Pseudouridylation of tRNA-Derived Fragments Steers Translational Control in Stem Cells［J］. Cell，2018，173（5）：1204-1216.e26. doi:10.1016/j.cell.2018.03.008
19 ZHANG D Y， MING G L， SONG H. PUS7： A targetable epitranscriptomic regulator of glioblastoma growth［J］. Trends Pharmacol Sci， 2021， 42（12）： 976-978. doi:10.1016/j.tips.2021.10.002
20 WU Y， PENG S， CHENG B， et al. FOXA1-dependent PUS1 regulates EIF3b stability in a non-enzymatic pathway mediating prostate cancer bone metastasis［J］. Int J Biol Sci， 2024， 20（11）： 4566-4584. doi:10.7150/ijbs.100905
21 HU Y X， DIAO L T， HOU Y R， et al. Pseudouridine synthase 1 promotes hepatocellular carcinoma through mRNA pseudouridylation to enhance the translation of oncogenic mRNAs［J］.Hepatology， 2024，80（5）：1058-1073. doi:10.1097/hep.0000000000000702
22 BARBIERI I， KOUZARIDES T. Role of RNA modifications in cancer［J］.Nat Rev Cancer， 2020， 20（6）： 303-322. doi:10.1038/s41568-020-0253-2
23 SADRKHANLOO M， ENTEZARI M， OROUEI S， et al. STAT3-EMT axis in tumors： Modulation of cancer metastasis， stemness and therapy response［J］. Pharmacol Res， 2022， 182： 106311. doi:10.1016/j.phrs.2022.106311
24 Barzegar Behrooz A， Talaie Z， Jusheghani F， et al. Wnt and PI3K/Akt/mTOR Survival Pathways as Therapeutic Targets in Glioblastoma［J］. Int J Mol Sci， 2022， 23（3）： 1353. doi:10.3390/ijms23031353
25 WU F， YANG J， LIU J， et al. Signaling pathways in cancer-associated fibroblasts and targeted therapy for cancer［J］. Signal Transduct Target Ther， 2021， 6（1）： 218. doi:10.1038/s41392-021-00641-0
26 MANNING B D， TOKER A.AKT/PKB Signaling： Navigating the Network［J］.Cell. 2017，169（3）：381-405. doi:10.1016/j.cell.2017.04.001
27 HUANG L， CHEN W， TAN Z， et al. Mrc1+ macrophage-derived IGF1 mitigates crystal nephropathy by promoting renal tubule cell proliferation via the AKT/Rb signaling pathway［J］. Theranostics， 2024， 14（4）： 1764-1780. doi:10.7150/thno.89174
28 ZUO Y， ZHANG C Z， REN Q， et al. Activation of mitochondrial-associated apoptosis signaling pathway and inhibition of PI3K/Akt/mTOR signaling pathway by voacamine suppress breast cancer progression［J］. Phytomedicine， 2022， 99： 154015. doi:10.1016/j.phymed.2022.154015
Options
Outlines

/

〈 〉